Led by two former Gilead Sciences Inc. executives who played key roles in developing and launching Viread, ContraVir Pharmaceuticals Inc. is reorganizing its scientific advisory board to change the biotech's therapeutic focus from shingles to hepatitis B as it advances a pair of candidates that it thinks could play key roles in next-wave HBV combination therapy, similar to advances seen previously in HIV and hepatitis C.
Existing advisory board member Carol Brosgart, formerly the VP of clinical research at Gilead who oversaw global development of HBV...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?